Sarcopenia
Conditions
Interventions
This is a clinical, randomized, controlled, two-arm, triple-blind study. A total of 100 people who meet the eligibility criteria will be probabilistically allocated into one of the groups (Experimenta
SP6.051.227
Sponsors
Universidade Federal de São Paulo
Escola Paulista de Medicina
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Volunteers diagnosed with some type of cancer in the gastrointestinal tract confirmed by biopsy or imaging; both genders; age over 18 years, Performance Status of Eastern Cooperative Oncology Group (ECOG) score less than or equal to 3; SARC-CalF greater than or equal to 11; decreased muscle mass; and/or decreased strength.
Exclusion criteria
Exclusion criteria: Volunteers using the chemotherapy drug Irinotecan; in dietary use of curcumin or supplements with curcuminoids or thermogenic; anticoagulants; presence of acute infection during the protocol; pregnant women; lactating women; cognitive limitations; physical limitations that prevent data collection; diagnosis of liver and kidney pathologies, gastric ulcer; participation in other clinical trials; use of Enteral or Parenteral Nutrition Therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to find an increase in strength of at least 20%, which will be evaluated by means of dynamometry, in the curcumin group, after 3 months of supplementation. | — |
Secondary
| Measure | Time frame |
|---|---|
| An improvement in cell quality is expected, with an increase of 15% in the Phase Angle measurement, obtained through the evaluation of body composition by Tetrapolar Electrical Bioimpedance, in the turmeric group, after 3 months of supplementation. | — |
Countries
Brazil
Contacts
Public ContactMagali Costa
Universidade Federal de São Paulo
Outcome results
None listed